‘You have to get up on the podi­um’: In­com­ing BIO chair Paul Hast­ings on di­ver­si­ty, drug pric­ing and work­ing with the FDA

Paul Hast­ings’ day job as CEO of Nkar­ta has him talk­ing about nat­ur­al killer cells and their po­ten­tial ap­pli­ca­tions in can­cer. But through­out the pan­dem­ic you’ll like­ly re­mem­ber him in his oth­er role: As vice chair of BIO, the biotech trade group, he would of­ten sign his name right un­der chair­man (and Ovid CEO) Je­re­my Levin, call­ing for FDA in­de­pen­dence, stand­ing up for the right to vote, and en­cour­ag­ing oth­ers to speak out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER